TuHURA Biosciences Inc. (HURA)
| Bid | 3.8 |
| Market Cap | 170.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.84M |
| EPS (ttm) | -1.21 |
| PE Ratio (ttm) | -3.23 |
| Forward PE | -4.84 |
| Analyst | Buy |
| Ask | 3.98 |
| Volume | 57,429 |
| Avg. Volume (20D) | 217,734 |
| Open | 3.77 |
| Previous Close | 3.78 |
| Day's Range | 3.76 - 3.96 |
| 52-Week Range | 1.80 - 14.60 |
| Beta | 0.79 |
About HURA
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL....
Analyst Forecast
According to 2 analyst ratings, the average rating for HURA stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 194.12% from the latest price.
Stock Forecasts
1 month ago · accessnewswire.com
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH ConferenceLive webcast fireside chat on Tuesday, March 18th at 8:30 AM PT TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-on...
2 months ago · accessnewswire.com
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceOn-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company dev...